1. Home
  2. PRAX

as of 02-12-2026 1:28pm EST

$331.83
+$8.54
+2.64%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Founded: 2015 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 8.6B IPO Year: 2020
Target Price: $519.60 AVG Volume (30 days): 540.8K
Analyst Decision: Strong Buy Number of Analysts: 15
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -12.92 EPS Growth: N/A
52 Week Low/High: $26.70 - $328.60 Next Earning Date: 02-19-2026
Revenue: $7,463,000 Revenue Growth: 364.98%
Revenue Growth (this year): -99.49% Revenue Growth (next year): 29535.93%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -228921000.0 FCF Growth: N/A

AI-Powered PRAX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 19 hours ago

AI Recommendation

hold
Model Accuracy: 73.89%
73.89%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Praxis Precision Medicines Inc. News

PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing

All PRAX News

Share on Social Networks: